Thus, the combination of a small molecule-based inhibitor of ALK with either a STAT3 inhibitor or an miRNA inhibitor may be a useful strategy to prevent chemoresistance in patients with ALK(+) ALCL and other ALK(+) malignancies. This evidence concerns the gene ALK and anaplastic large cell lymphoma.